Medicaroid, Inc. Sustainability Profile
Medicaroid, Inc., a pioneering force in the healthcare technology sector, is headquartered in the United States and operates across various regions, focusing on innovative medical solutions. Founded in 2015, the company has rapidly established itself as a leader in the development of advanced robotic systems and AI-driven healthcare applications. Specialising in robotic-assisted surgery and rehabilitation technologies, Medicaroid's core products are designed to enhance surgical precision and improve patient outcomes. Their unique approach combines cutting-edge robotics with intuitive user interfaces, setting them apart in a competitive market. With a commitment to advancing medical practices, Medicaroid has achieved significant milestones, including partnerships with leading hospitals and research institutions. Their dedication to innovation positions them as a key player in the evolving landscape of healthcare technology.
DitchCarbon Score
How does Medicaroid, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Medicaroid, Inc.'s score of 44 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Medicaroid, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of reported figures. The company is a current subsidiary of Sysmex Corporation, which means that any climate commitments or emissions data may be inherited from its parent organisation. As part of its climate strategy, Medicaroid, Inc. aligns with initiatives from Sysmex Corporation, which has set various reduction targets and participates in industry-standard climate frameworks. However, specific reduction targets or achievements for Medicaroid, Inc. are not detailed in the available information. The absence of direct emissions data suggests that Medicaroid, Inc. may still be in the process of establishing its own climate commitments or reporting mechanisms. As a subsidiary, it is likely to follow the broader sustainability goals set by Sysmex Corporation, which may include commitments to reduce Scope 1, 2, and 3 emissions in line with global climate standards. In summary, while Medicaroid, Inc. does not currently report specific emissions data or reduction targets, it is positioned within a corporate family that is engaged in climate initiatives, potentially influencing its future commitments and performance in carbon emissions reduction.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 5,559,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 20,278,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | 00,000,000 | 00,000,000 | 00,000,000 | - | - | - | 000,000,000 | 000,000,000 |
How Carbon Intensive is Medicaroid, Inc.'s Industry?
How Carbon Intensive is Medicaroid, Inc.'s Location?
Medicaroid, Inc.'s Scope 3 Categories Breakdown
Medicaroid, Inc.'s Scope 3 emissions, which decreased by 4% last year and increased significantly since 2016, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 34% of Scope 3 emissions.
Top Scope 3 Categories
Medicaroid, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Medicaroid, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
